IBIO
Price
$0.78
Change
-$0.00 (-0.00%)
Updated
Oct 15, 11:38 AM (EDT)
Capitalization
75.24M
33 days until earnings call
Intraday BUY SELL Signals
WVE
Price
$3.12
Change
+$0.03 (+0.97%)
Updated
Oct 15, 11:22 AM (EDT)
Capitalization
723.17M
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IBIO vs WVE

IBIO vs WVE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IBIO vs. WVE commentary
Oct 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBIO is a Hold and WVE is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IBIO with price predictions
Oct 14, 2026

Momentum Indicator for IBIO turns negative, indicating new downward trend

IBIO saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 72 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for IBIO turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 38 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for IBIO entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +8.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBIO advanced for three days, in 188 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

IBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.878) is normal, around the industry mean (26.782). P/E Ratio (0.654) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. IBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for WVE with price predictions
Oct 14, 2026

WVE in -5.79% downward trend, falling for three consecutive days on October 14, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where WVE declined for three days, in 252 of 292 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for WVE entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +6.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where WVE advanced for three days, in 209 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

WVE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.595) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (12.953) is also within normal values, averaging (437.542).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. WVE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IBIO vs WVE: Fundamental Ratings
IBIO
WVE
OUTLOOK RATING
1..100
6359
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
9092
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WVE's Valuation (21) in the Biotechnology industry is somewhat better than the same rating for IBIO (75). This means that WVE’s stock grew somewhat faster than IBIO’s over the last 12 months.

WVE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IBIO (100). This means that WVE’s stock grew similarly to IBIO’s over the last 12 months.

WVE's SMR Rating (98) in the Biotechnology industry is in the same range as IBIO (98). This means that WVE’s stock grew similarly to IBIO’s over the last 12 months.

IBIO's Price Growth Rating (90) in the Biotechnology industry is in the same range as WVE (92). This means that IBIO’s stock grew similarly to WVE’s over the last 12 months.

IBIO's P/E Growth Rating (98) in the Biotechnology industry is in the same range as WVE (100). This means that IBIO’s stock grew similarly to WVE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBIOWVE
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 4 days ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 28 days ago
83%
Bullish Trend 15 days ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
COMPARISON
Comparison
Oct 15, 2026
Stock price -- (IBIO: $0.78 vs. WVE: $3.09)
Brand notoriety: IBIO and WVE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBIO: 236% vs. WVE: 86%
Market capitalization -- IBIO: $75.24M vs. WVE: $723.17M
IBIO [@Biotechnology] is valued at $75.24M. WVE’s [@Biotechnology] market capitalization is $723.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBIO’s FA Score shows that 0 FA rating(s) are green while WVE’s FA Score has 1 green FA rating(s).

  • IBIO’s FA Score: 0 green, 5 red.
  • WVE’s FA Score: 1 green, 4 red.
According to our system of comparison, WVE is a better buy in the long-term than IBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBIO’s TA Score shows that 4 TA indicator(s) are bullish while WVE’s TA Score has 4 bullish TA indicator(s).

  • IBIO’s TA Score: 4 bullish, 4 bearish.
  • WVE’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, WVE is a better buy in the short-term than IBIO.

Price Growth

IBIO (@Biotechnology) experienced а -22.69% price change this week, while WVE (@Biotechnology) price change was -12.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.30%. For the same industry, the average monthly price growth was -12.97%, and the average quarterly price growth was -18.96%.

Reported Earning Dates

IBIO is expected to report earnings on Nov 17, 2026.

WVE is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IBIO
Daily Signal:
Gain/Loss:
WVE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GXPE39.720.97
+2.52%
Global X PureCap MSCI Energy ETF (GXPE)
IDNA41.280.49
+1.20%
iShares Genomics Immunology and Healthcare ETF (IDNA)
IBIH25.020.05
+0.20%
iShares iBonds Oct 2031 Term TIPS ETF (IBIH)
SQS28.17N/A
N/A
Sapient Quality Select ETF
ISTM28.56-0.95
-3.22%
iShares Strategic Metals ETF (ISTM)

WVE and

Correlation & Price change

A.I.dvisor indicates that over the last year, WVE has been loosely correlated with GPCR. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if WVE jumps, then GPCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WVE
1D Price
Change %
WVE100%
-1.59%
GPCR - WVE
64%
Loosely correlated
-1.93%
KYMR - WVE
52%
Loosely correlated
+0.14%
IBIO - WVE
47%
Loosely correlated
-0.13%
FRMM - WVE
44%
Loosely correlated
-7.40%
ELVN - WVE
41%
Loosely correlated
-0.53%
More